Search
Arrowhead Pharmaceuticals Inc
ARWRAdd to Watchlist
80.500USD
+1.610+2.04%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
11.34BMarket Cap
LossP/E TTM
More Details of Arrowhead Pharmaceuticals Inc Company
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
Arrowhead Pharmaceuticals Inc Info
Ticker SymbolARWR
Company nameArrowhead Pharmaceuticals Inc
IPO dateDec 14, 1993
CEOAnzalone (Christopher Richard)
Number of employees711
Security typeOrdinary Share
Fiscal year-endDec 14
Address177 E Colorado Blvd
CityPASADENA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91105
Phone16266964702
Websitehttps://arrowheadpharma.com/
Ticker SymbolARWR
IPO dateDec 14, 1993
CEOAnzalone (Christopher Richard)
Company Executives of Arrowhead Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.79M
-0.35%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
547.41K
+4.20%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
123.06K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
69.05K
--
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
60.04K
-4.95%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
59.02K
+21.69%
Ms. Victoria (Vicki) Vakiener
Ms. Victoria (Vicki) Vakiener
Independent Director
Independent Director
35.72K
--
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
33.60K
--
Mr. Vincent Anzalone
Mr. Vincent Anzalone
Investor Relations
Investor Relations
--
--
Mr. William D. Waddill
Mr. William D. Waddill
Lead Independent Director
Lead Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.79M
-0.35%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
547.41K
+4.20%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
123.06K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
69.05K
--
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
60.04K
-4.95%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
59.02K
+21.69%
FAQs
Who are the top five shareholders of Arrowhead Pharmaceuticals Inc?
The top five shareholders of Arrowhead Pharmaceuticals Inc are: Dr. Christopher Richard (Chris) Anzalone, Ph.D.
How many institutions hold shares of Arrowhead Pharmaceuticals Inc (ARWR)?
As of 2026Q1, 735 institutions hold shares of Arrowhead Pharmaceuticals Inc, with a combined market value of approximately 111.75M, accounting for 79.34% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -13922396.00.
